NYSEMKT: SCPXScorpius Holdings Inc Stock
$0.16+0.00 (+0%)
Updated Apr 17, 2024
SCPX Price
$0.16
Fair Value Price
N/A
Market Cap
$4.17M
52 Week Low
$0.15
52 Week High
$0.89
P/E
-0.08x
P/B
0.11x
P/S
6.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.23M
Earnings
-$51.96M
Gross Margin
29.1%
Operating Margin
-2,497.16%
Profit Margin
-2,333.5%
Debt to Equity
1.01
Operating Cash Flow
-$38M
Beta
0.72
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SCPX Overview
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Durham, North Carolina and currently employs 30 full-time employees. The firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. The company is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SCPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCPX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCPX is good value based on its book value relative to its share price (0.11x), compared to the US Biotechnology industry average (5.83x)
P/B vs Industry Valuation
SCPX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SCPX due diligence checks available for Premium users.
Be the first to know about important SCPX news, forecast changes, insider trades & much more!
SCPX News
Valuation
SCPX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
15.83x
Market
41.64x
SCPX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
5.83x
SCPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCPX's financial health
Profit margin
Revenue
$723.1k
Net Income
-$13.1M
Profit Margin
-1,816.1%
SCPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCPX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$69.9M
Liabilities
$36.5M
Debt to equity
1.01
SCPX's short-term liabilities ($24.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCPX's short-term assets ($24.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCPX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.5M
Investing
$7.8M
Financing
$164.6k
SCPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCPX vs Biotech Stocks
Scorpius Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.